ERYTECH Pharma S.A. Logo

ERYTECH Pharma S.A.

Develops red blood cell-based therapies for cancer and orphan diseases.

ERYP | PA

Overview

Corporate Details

ISIN(s):
FR0010417360 (+2 more)
LEI:
969500U8ZZCODU8A9374
Country:
France
Address:
60 AVENUE ROCKEFELLER, 69008 LYON

Description

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2019-01-08 18:00
Communiqué
French 211.0 KB
2018-12-05 18:00
Communiqué de presse
French 176.3 KB
2018-12-05 18:00
Press Release
English 86.3 KB
2018-11-15 22:05
Press Release
English 326.2 KB
2018-11-15 22:05
Communiqué de presse
French 411.6 KB
2018-11-13 09:49
Franchissement de seuils et déclaration d'intention
French 27.5 KB
2018-11-05 18:00
Communiqué de presse
French 334.4 KB
2018-11-05 18:00
Press Release
English 159.1 KB
2018-11-05 07:00
Press release
English 330.0 KB
2018-11-05 07:00
Communiqué
French 366.7 KB
2018-06-20 07:30
PDF
English 325.8 KB
2018-06-20 07:30
PDF
French 425.6 KB
2018-06-15 07:30
Erytech
English 330.5 KB
2018-06-15 07:30
Erytech
French 434.7 KB
2018-06-07 07:30
English
English 270.1 KB

Automate Your Workflow. Get a real-time feed of all ERYTECH Pharma S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ERYTECH Pharma S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ERYTECH Pharma S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-06-23 N/A Other Other 3,697,533 2,255,495.13 EUR
2023-06-23 N/A Other Other 71,839 43,821.79 EUR
2023-06-23 N/A Other Other 54,862 33,465.82 EUR

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.